Company news
Innoviva, Inc. (NASDAQ:INVA) news
Every Innoviva, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
August 5, 2026
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
June 16, 2026
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
May 6, 2026
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmar...
March 10, 2026
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
February 25, 2026
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenita...
December 12, 2025
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplica...
December 11, 2025
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
November 25, 2025
Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health
November 13, 2025
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
November 5, 2025
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
October 21, 2025
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek ...
October 20, 2025
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
October 7, 2025
Innoviva to Participate in Upcoming Investor Conferences
August 26, 2025
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical...
August 13, 2025
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
August 12, 2025
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
August 6, 2025
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Da...
June 12, 2025
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncom...
June 10, 2025
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of B...
May 20, 2025
Innoviva Reports First Quarter 2025 Financial Results, Highlights Recent Company Progress
May 8, 2025
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
May 7, 2025
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
March 5, 2025
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
February 26, 2025
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 6, 2025
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (cefto...
December 16, 2024
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
November 26, 2024
Innoviva to Participate in the UBS Global Healthcare Conference
November 12, 2024
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
November 6, 2024
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
July 31, 2024
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 3, 2024
Innoviva to Participate in the BofA Securities Health Care Conference
May 8, 2024
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
May 8, 2024
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID...
April 24, 2024
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
February 29, 2024
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
November 1, 2023
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 1, 2023
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
October 11, 2023
Innoviva to Participate in the Cantor Global Healthcare Conference
September 19, 2023
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (...
September 18, 2023
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 2, 2023
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
July 11, 2023
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 6, 2023
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for...
May 23, 2023
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetob...
May 11, 2023
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 9, 2023
Innoviva Announces Retirement of Board Chairman
April 28, 2023
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023